First round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.
Representative SPR sensorgrams of ORF1 “3rd Gen.” nanobody multimers with “5xCys Tail.
Second round of screening of newly developed “3rd generation” assays using dimeric nanobody detectors.
(obtained from Drapkin Lab at the University of Pennsylvania).Circulating CA125 and HE4 levels, as measured by Simoa, in ovarian cancer patient cohort.
Circulating ORF1p (first generation Simoa assay) versus prostate-specific antigen (PSA).
Circulating ORF1p levels in patients with chronic liver disease or systemic lupus erythematous.
De-identified patient information for survival analysis.
Second round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.